Description
Lenalidomide (Revlimid, CC-5013) can inhibit TNF-alpha secretion with IC50 of 13 nM.
Storage
2 years at -20 centigrade
Molecular Formula
C13H13N3O3
Chemical Name
3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Solubility
DSMO 52 mg/mL Water
In vitro
Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-kappaB. Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined.
In vivo
enalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg).
Download Datasheet